Sonic Healthcare Limited (SAB) Stock Price & Analysis
SAB Stock Chart & Stats
- Day’s Range
- EUR 11.90 - EUR 12.07
- 52-Week Range
- EUR 11.07 - EUR 14.30
- Previous Close
- EUR 11.83
- Volume
- 0
- Average Volume (3M)
- 127
- Market Cap
- EUR 6.07B
- Enterprise Value
- EUR 15.64B
- Total Cash (Recent Filing)
- EUR 653.70M
- Total Debt (Recent Filing)
- EUR 5.84B
- Price to Earnings (P/E)
- 15.9
- Beta
- 0.42
- Next Earnings
- Feb 22, 2027 (Est.)
- EPS Estimate
- 0.33
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 5.52%
Bulls Say, Bears Say
Bulls Say
Resilient Revenue And Advanced Diagnostics Growth
Recurring demand for pathology and imaging, supported by healthcare utilization and specialized testing, provides a durable growth base. Strong advanced diagnostics performance also indicates improving service mix and opportunities beyond routine testing.
Acquisition Scale And Synergy Capture
Successful integration of LADR strengthens Sonic’s European scale and laboratory network density while providing identifiable cost synergies. Further benefits over two years could support operating leverage and reinforce its competitive position.
Balance Sheet Flexibility And Disciplined Capital Management
Despite recent investment and acquisitions, Sonic retains meaningful funding capacity and has demonstrated asset monetization discipline. This supports continued investment, debt management and shareholder distributions without indicating immediate balance-sheet stress.
Bears Say
Structural Margin Compression And Weaker Returns
The sustained decline from prior profitability peaks suggests cost, reimbursement or business-mix pressure rather than a temporary fluctuation. Lower margins and a 7.3% return on equity reduce earnings resilience and limit operating leverage.
Higher Leverage And Weaker Cash Conversion
Rising debt alongside weaker conversion of accounting profit into free cash flow reduces financial flexibility. This can constrain future acquisitions, dividends or technology investment if operating conditions weaken or funding costs remain elevated.
Regulatory And Execution Pressure Across Key Markets
Diagnostics reimbursement and outsourced healthcare contracts remain exposed to policy and labor changes. The Swiss fee reduction and delayed UK contract benefits could create persistent revenue and margin pressure, highlighting geographic execution risk.
SAB FAQ
What was Sonic Healthcare Limited’s price range in the past 12 months?
What is Sonic Healthcare Limited’s market cap?
When is Sonic Healthcare Limited’s upcoming earnings report date?
How were Sonic Healthcare Limited’s earnings last quarter?
Is Sonic Healthcare Limited overvalued?
Does Sonic Healthcare Limited pay dividends?
What is Sonic Healthcare Limited’s EPS estimate?
How many shares outstanding does Sonic Healthcare Limited have?
What happened to Sonic Healthcare Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sonic Healthcare Limited?
What is the TipRanks Smart Score and how is it calculated?
Sonic Healthcare Limited Stock Smart Score
Company Description
Sonic Healthcare Limited
Sonic Healthcare Limited delivers medical diagnostic services to a diverse clientele, including medical professionals, hospitals, public health organizations, and individual patients. The company's services encompass a broad spectrum of laboratory medicine and pathology testing, covering biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal diagnostics, toxicology, and other related functions. Furthermore, Sonic provides extensive radiology services, such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. Its offerings also extend to primary care medical services, featuring general practice clinics, occupational health, specialized skin cancer clinics, after-hours GP services, IT solutions for general practices, and various community-based healthcare programs. Operating internationally, the company has a significant presence in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, and Belgium. Founded in 1934, Sonic Healthcare Limited is headquartered in Sydney, Australia.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James Pacey Newcombe
- Employees
- 47,000
- Website
- www.sonichealthcare.com
- Address
- Grosvenor Place, Sydney, NSW, 2000, AU
Sonic Healthcare Limited (SAB) Earnings & Revenues
SAB Earnings Call
Earnings Call SentimentPositive
The call conveyed a largely positive operational and financial picture: strong FY2026 headline results (13% revenue growth, 11% EBITDA growth, 17% NPAT growth), clear progress on acquisitions and synergy capture (notably LADR), solid organic and advanced diagnostics growth, and active capital management. Notable challenges were highlighted—regulatory fee cuts in Switzerland (~CHF 20m), integration and labor cost pressures in the U.K., legacy software impairments (AUD 83m), U.S. market headwinds and uncertainty over potential PAMA cuts, and elevated FY2026 capex and interest costs. Management has provided FY2027 guidance that factors in many of these headwinds and set out remediation initiatives (U.S. operating review, continued synergy capture, digital transformation). On balance, the positives (growth, acquisitions performing, synergy delivery, strong cash/capital actions) outweigh the identified headwinds, although risks remain in specific markets and from regulatory/FX exposures.
View all DE:SAB earnings summariesSAB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 2 | 7 |
| Technical Analysis | 4 | 2 | 4 |
| Moving Averages | 9 | 0 | 3 |